Vitro Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Vitro Biopharma, an innovative biotechnology company, reported increased net losses for fiscal year 2025, driven by debt extinguishment, while advancing its cell therapy pipeline for autoimmune and inflammatory disorders.
10-K: Vitro Biopharma's 10-K Filing Reveals Focus on Cell Therapy Development Amidst Financial Challenges
Vitro Biopharma's 10-K filing highlights its ongoing development of AlloRx Stem Cell therapy for autoimmune and inflammatory diseases, while also addressing financial uncertainties and operational risks.